Fannin Innovation Studio

Procyrion is a clinical-stage medical device company that designs and manufactures catheter-based circulatory support devices, most notably the Aortix heart pump. The percutaneous device is implanted via the leg through a catheter between the heart and kidneys to unload the failing heart, improve perfusion to vital organs, and rest the heart to aid recovery in patients with heart failure who are not responding to medications. It aims to decongest acute decompensated heart failure and reduce afterload while preserving kidney perfusion, enabling treatment of patients who are too sick for conventional therapies. Founded in 2005 and based in Houston, Texas.

Allterum Therapeutics is a biopharmaceutical company focused on developing innovative treatments for relapsed acute lymphoblastic leukemia and other cancers that express the IL-7 receptor. The company is advancing a monoclonal antibody, specifically the 4A10 antibody, which was originally developed at the National Cancer Institute and is designed to selectively target and eliminate cancer cells. This targeted approach aims to minimize the side effects commonly associated with conventional chemotherapy, particularly benefiting pediatric patients with relapsed or refractory T-cell malignancies. Additionally, Allterum Therapeutics is investigating the potential of its therapies for relapsed or refractory solid tumors characterized by IL-7R over-expression.

Procyrion is a clinical-stage medical device company that designs and manufactures catheter-based circulatory support devices, most notably the Aortix heart pump. The percutaneous device is implanted via the leg through a catheter between the heart and kidneys to unload the failing heart, improve perfusion to vital organs, and rest the heart to aid recovery in patients with heart failure who are not responding to medications. It aims to decongest acute decompensated heart failure and reduce afterload while preserving kidney perfusion, enabling treatment of patients who are too sick for conventional therapies. Founded in 2005 and based in Houston, Texas.

Pulmotect, Inc. is a biopharmaceutical company based in Houston, Texas, specializing in the development of inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007, the company's innovative approach focuses on enhancing the innate immune system to provide rapid and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as potential bioterror agents. Pulmotect’s lead product, PUL-042, is a clinical-stage inhaled therapeutic that delivers immediate immune response, offering broad-spectrum protection that lasts for several days. By boosting the body’s natural defenses, Pulmotect aims to significantly reduce morbidity and mortality in vulnerable patient populations at risk of severe respiratory diseases.

Pulmotect, Inc. is a biopharmaceutical company based in Houston, Texas, specializing in the development of inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007, the company's innovative approach focuses on enhancing the innate immune system to provide rapid and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as potential bioterror agents. Pulmotect’s lead product, PUL-042, is a clinical-stage inhaled therapeutic that delivers immediate immune response, offering broad-spectrum protection that lasts for several days. By boosting the body’s natural defenses, Pulmotect aims to significantly reduce morbidity and mortality in vulnerable patient populations at risk of severe respiratory diseases.

Procyrion is a clinical-stage medical device company that designs and manufactures catheter-based circulatory support devices, most notably the Aortix heart pump. The percutaneous device is implanted via the leg through a catheter between the heart and kidneys to unload the failing heart, improve perfusion to vital organs, and rest the heart to aid recovery in patients with heart failure who are not responding to medications. It aims to decongest acute decompensated heart failure and reduce afterload while preserving kidney perfusion, enabling treatment of patients who are too sick for conventional therapies. Founded in 2005 and based in Houston, Texas.